Predicting prostate biopsy outcome: Prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers

Clinica Chimica Acta

Volumn 413, Issue 15-16, 2012, Pages 1274-1278

  Ferro, Matteo ^a   Bruzzese, Dario ^a   Perdonà, Sisto ^b   Mazzarella, Claudia ^a   Marino, Ada ^a   Sorrentino, Alessandra ^a   Di Carlo, Angelina ^c   Autorino, Riccardo ^d   Di Lorenzo, Giuseppe ^a   Buonerba, Carlo ^a   Altieri, Vincenzo ^a   Mariano, Angela ^a   Macchia, Vincenzo ^a   Terracciano, Daniela ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

p2PSA; PCA3; Phi; Prostate biopsy; Prostate cancer

Indexed keywords

PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; GOLD STANDARD; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE HEALTH INDEX; PROSTATIC INTRAEPITHELIAL NEOPLASIA; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861330017     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2012.04.017     Document Type: Article

References (36)

1. Bostwick D.G., Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Pract 1995, 191:828-832.
2. Schlesinger C., Bostwick D.G., Iczkowski K.A. High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation: predictive value for cancer in current practice. Am J Surg Pathol 2005, 29:1201-1207.
3. Epstein J.I., Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. J Urol 2006, 175:820-834.
4. Heidenreich A., Bellmunt J., Bolla M., et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011, 59:61-71.
5. Stephan C., Kramer J., Meyer H.A., et al. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007, 99:1427-1431.
6. Gosselaar C., Kranse R., Roobol M.J., Roemeling S., Schroder F.H. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 2008, 68:985-993.
7. Evans C.P. Identification of molecular targets in urologic oncology. World J Urol 2009, 27:3-8.
8. Prior C., Guillen-Grima F., Robles J.E., et al. Use of a combination of biomarkers in serum and urine to improve detection of prostate cancer. World J Urol 2010, 28:681-686.
9. Bessede T., Malavaud B. The new biomarkers of prostate cancer. Prog Urol 2011, 21(Suppl. 2):S63-S67.
10. Deras I.L., Aubin S.M., Blase A., et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol 2008, 179:1587-1592.
11. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008, 54:1081-1088.
12. Marks L.S., Fradet Y., Deras I.L., et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007, 69:532-535.
13. Roobol M.J., Schroder F.H., van Leeuwen P., et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010, 58:475-481.
14. Perdona S., Cavadas V., Di Lorenzo G., et al. Prostate cancer detection in the "grey area" of prostate-specific antigen below 10ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol 2011, 59:81-87.
15. Jansen F.H., van Schaik R.H., Kurstjens J., et al. Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 2010, 57:921-927.
16. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 2000, 60:756-759.
17. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4ng/ml. J Urol 2003, 170:2181-2185.
18. Tuck M.K., Chan D.W., Chia D., et al. Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res 2009, 8:113-117.
19. Shariat S.F., Semjonow A., Lilja H., Savage C., Vickers A.J., Bjartell A. Tumor markers in prostate cancer I: blood-based markers. Acta Oncol 2011, 50(Suppl. 1):61-75.
20. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52:1089-1095.
21. Scattoni V., Raber M., Abdollah F., et al. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy. Eur Urol 2010, 57:1-8.
22. Tosoian J.J., Loeb S., Kettermann A., et al. Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol 2010, 183:534-538.
23. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
24. Steyerberg E.W., Eijkemans M.J., Harrell F.E., Habbema J.D. Prognostic modelling with logistic regression analysis: a comparison of selection and estimation methods in small data sets. Stat Med 2000, 19:1059-1079.
25. Steyerberg E.W., Harrell F.E., Borsboom G.J., Eijkemans M.J., Vergouwe Y., Habbema J.D. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J Clin Epidemiol 2001, 54:774-781.
26. Epstein J.I., Walsh P.C., Carmichael M., Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374.
27. Schroder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-1328.
28. Guazzoni G., Nava L., Lazzeri M., et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011, 60:214-222.
29. Ploussard G., de la Taille A. Urine biomarkers in prostate cancer. Nat Rev Urol 2010, 7:101-109.
30. Ploussard G., Haese A., Van Poppel H., et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies?. BJU Int 2010, 106:1143-1147.
31. Morote J., Rigau M., Garcia M., et al. Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia. World J Urol 2010, 28:677-680.
32. Wang R., Chinnaiyan A.M., Dunn R.L., Wojno K.J., Wei J.T. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009, 115:3879-3886.
33. Klecka J., Holubec L., Pesta M., et al. Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis. Anticancer Res 2010, 30:665-670.
34. Hull D., Ma J., Singh H., Hossain D., Qian J., Bostwick D.G. Precursor of prostate-specific antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 90 cases. BJU Int 2009, 104:915-918.
35. Montironi R., Mazzucchelli R., Lopez-Beltran A., Cheng L., Scarpelli M. Mechanisms of disease: high-grade prostatic intraepithelial neoplasia and other proposed preneoplastic lesions in the prostate. Nat Clin Pract Urol 2007, 4:321-332.
36. Netto G.J., Epstein J.I. Widespread high-grade prostatic intraepithelial neoplasia on prostatic needle biopsy: a significant likelihood of subsequently diagnosed adenocarcinoma. Am J Surg Pathol 2006, 30:1184-1188.